Multi-institutional analysis of extracranial oligometastatic colorectal cancer patients treated with stereotactic body radiation therapy: TROD 02-008 study.

IF 2.7 3区医学 Q3 ONCOLOGY

Strahlentherapie und Onkologie Pub Date : 2024-11-01 Epub Date: 2024-08-19 DOI:10.1007/s00066-024-02291-x

Ozan Cem Guler, Pervin Hurmuz, Banu Atalar, Yıldız Guney, Esra Kaytan Saglam, Serap Akyurek, Yasemin Bolukbasi, Zeynep Gural, Fuzuli Tugrul, Aylin Korcum, Cenk Ahmet Sen, Berna Akkus Yildirim, Didem Colpan Oksuz, Meral Kurt, Zeliha Guzeloz, Gorkem Aksu, Mert Saynak, Gamze Aksu, Cem Onal

{"title":"Multi-institutional analysis of extracranial oligometastatic colorectal cancer patients treated with stereotactic body radiation therapy: TROD 02-008 study.","authors":"Ozan Cem Guler, Pervin Hurmuz, Banu Atalar, Yıldız Guney, Esra Kaytan Saglam, Serap Akyurek, Yasemin Bolukbasi, Zeynep Gural, Fuzuli Tugrul, Aylin Korcum, Cenk Ahmet Sen, Berna Akkus Yildirim, Didem Colpan Oksuz, Meral Kurt, Zeliha Guzeloz, Gorkem Aksu, Mert Saynak, Gamze Aksu, Cem Onal","doi":"10.1007/s00066-024-02291-x","DOIUrl":null,"url":null,"abstract":"Purpose: To investigate the treatment outcomes of extracranial oligometastatic colorectal cancer (CRC) patients treated with stereotactic body radiotherapy (SBRT).Materials and methods: The clinical data of 388 extra-cranial oligometastatic CRC (≤ 5 lesions) patients and 463 lesions treated with SBRT at 19 cancer institutions were retrospectively analyzed. The prognostic factors predicting overall survival (OS), progression-free survival (PFS), and local control (LC) were assessed in uni- and multivariable analyses.Results: The median age was 62 years (range, 29-92 years). The majority of the patients (90.5%) received surgery and systemic treatment for their primary tumor, had ≤ 2 metastasis (83.3%), had single organ involvement (90.3%), and staged using flouro-deoxyglucose positron emission tomography (FDG-PET/CT) (76%). The median fraction and total radiation doses were 10 Gy (range: 6-34 Gy) and 50 Gy (range: 8-64 Gy), respectively, delivered in a median of 4 fractions (range: 1-8). The median follow-up time for the entire cohort was 30.7 months (interquartile range: 27.0-34.3 months). The 3‑year OS, PFS, and LC rates were 64.0%, 42.3%, and 72.7%, respectively. The 3‑year LC rate was significantly higher in patients receiving BED10 ≥ 100 Gy than those receiving BED10 < 100 Gy (76.0% vs. 67.3%; p = 0.04). The 3‑year PFS and OS rates were higher in patients receiving BED10 ≥ 100 Gy than those receiving BED10 < 100 Gy (33.2% vs. 25.2%; p = 0.03; 53.7% vs. 44.8%; p = 0.02). Single metastasis and complete response after SBRT were independent prognostic factors for survival in multivariable analysis.Conclusions: In this multi-center study, we demonstrated that SBRT is an effective treatment option of metastatic lesions in oligometastatic CRC patients by providing promising LC rates. Higher SBRT doses beyond BED10 ≥ 100 Gy were associated with improved LC and survival. LC of treated lesion and lower tumor burden after SBRT were associated with better outcomes.","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"958-966"},"PeriodicalIF":2.7000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Strahlentherapie und Onkologie","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00066-024-02291-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/19 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To investigate the treatment outcomes of extracranial oligometastatic colorectal cancer (CRC) patients treated with stereotactic body radiotherapy (SBRT).

Materials and methods: The clinical data of 388 extra-cranial oligometastatic CRC (≤ 5 lesions) patients and 463 lesions treated with SBRT at 19 cancer institutions were retrospectively analyzed. The prognostic factors predicting overall survival (OS), progression-free survival (PFS), and local control (LC) were assessed in uni- and multivariable analyses.

Results: The median age was 62 years (range, 29-92 years). The majority of the patients (90.5%) received surgery and systemic treatment for their primary tumor, had ≤ 2 metastasis (83.3%), had single organ involvement (90.3%), and staged using flouro-deoxyglucose positron emission tomography (FDG-PET/CT) (76%). The median fraction and total radiation doses were 10 Gy (range: 6-34 Gy) and 50 Gy (range: 8-64 Gy), respectively, delivered in a median of 4 fractions (range: 1-8). The median follow-up time for the entire cohort was 30.7 months (interquartile range: 27.0-34.3 months). The 3‑year OS, PFS, and LC rates were 64.0%, 42.3%, and 72.7%, respectively. The 3‑year LC rate was significantly higher in patients receiving BED₁₀ ≥ 100 Gy than those receiving BED₁₀ < 100 Gy (76.0% vs. 67.3%; p = 0.04). The 3‑year PFS and OS rates were higher in patients receiving BED₁₀ ≥ 100 Gy than those receiving BED₁₀ < 100 Gy (33.2% vs. 25.2%; p = 0.03; 53.7% vs. 44.8%; p = 0.02). Single metastasis and complete response after SBRT were independent prognostic factors for survival in multivariable analysis.

Conclusions: In this multi-center study, we demonstrated that SBRT is an effective treatment option of metastatic lesions in oligometastatic CRC patients by providing promising LC rates. Higher SBRT doses beyond BED₁₀ ≥ 100 Gy were associated with improved LC and survival. LC of treated lesion and lower tumor burden after SBRT were associated with better outcomes.

Abstract Image

查看原文本刊更多论文

对接受立体定向体放射治疗的颅外少转移性结直肠癌患者进行的多机构分析：TROD 02-008 研究。

目的：研究接受立体定向体放射治疗（SBRT）的颅外寡转移性结直肠癌（CRC）患者的治疗效果：回顾性分析了19家癌症机构的388例颅外少转移性结直肠癌（病灶数≤5）患者和463个病灶接受SBRT治疗的临床数据。通过单变量和多变量分析评估了预测总生存期（OS）、无进展生存期（PFS）和局部控制率（LC）的预后因素：中位年龄为62岁（29-92岁）。大多数患者（90.5%）的原发肿瘤接受了手术和全身治疗，转移灶≤2个（83.3%），单器官受累（90.3%），使用氟脱氧葡萄糖正电子发射断层扫描（FDG-PET/CT）进行分期（76%）。中位分次放射剂量和总放射剂量分别为10 Gy（范围：6-34 Gy）和50 Gy（范围：8-64 Gy），中位分次放射剂量为4次（范围：1-8次）。整个组群的中位随访时间为30.7个月（四分位间范围：27.0-34.3个月）。3年的OS、PFS和LC率分别为64.0%、42.3%和72.7%。接受BED10≥100 Gy治疗的患者3年LC率明显高于接受BED10 10≥100 Gy治疗的患者结论：在这项多中心研究中，我们证实了 SBRT 是治疗少转移性 CRC 转移病灶的有效方法，其 LC 率很高。BED10≥100Gy以上的SBRT剂量与LC和生存率的改善相关。SBRT治疗后病灶的LC和较低的肿瘤负荷与更好的预后相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Strahlentherapie und Onkologie 医学-核医学

CiteScore

5.70

自引率

12.90%

发文量

141

审稿时长

3-8 weeks

期刊介绍： Strahlentherapie und Onkologie, published monthly, is a scientific journal that covers all aspects of oncology with focus on radiooncology, radiation biology and radiation physics. The articles are not only of interest to radiooncologists but to all physicians interested in oncology, to radiation biologists and radiation physicists. The journal publishes original articles, review articles and case studies that are peer-reviewed. It includes scientific short communications as well as a literature review with annotated articles that inform the reader on new developments in the various disciplines concerned and hence allow for a sound overview on the latest results in radiooncology research. Founded in 1912, Strahlentherapie und Onkologie is the oldest oncological journal in the world. Today, contributions are published in English and German. All articles have English summaries and legends. The journal is the official publication of several scientific radiooncological societies and publishes the relevant communications of these societies.